Related Experiment Videos
[The best of 2001. Arterial hypertension]
1Service de pharmacologie, INSERM EMI 107, Hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris.
Insights
Angiotensin II antagonists reduce diabetic nephropathy progression in hypertensive type 2 diabetes patients. ACE inhibitor/diuretic therapy significantly lowers recurrent stroke risk in patients with prior stroke or transient ischemic attack.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Neurology
Context:
- Major clinical trials published in 2001 evaluated interventions for hypertensive patients with type 2 diabetes and those with a history of stroke.
- Diabetic nephropathy and stroke are significant complications in hypertensive patients.
Purpose:
- To summarize the findings of key clinical trials (IRMA, RENAAL, IDNT, PROGRESS) regarding the management of hypertension in specific patient populations.
- To assess the efficacy of Angiotensin II antagonists and ACE inhibitor/diuretic bitherapy in preventing disease progression and recurrence.
Summary:
- Angiotensin II antagonists (irbesartan, losartan) demonstrated a preventive effect on diabetic nephropathy progression in hypertensive patients with type 2 diabetes, irrespective of renal dysfunction stage.
- The PROGRESS study indicated that blood pressure reduction with ACE inhibitor/diuretic bitherapy (perindopril/indapamide) significantly decreased the risk of recurrent stroke in patients with a history of minor stroke or transient ischemic attack.
Impact:
- These findings highlight the importance of targeted antihypertensive therapies in managing complications associated with type 2 diabetes and cerebrovascular disease.
- The results provide evidence-based strategies for reducing the burden of diabetic nephropathy and stroke recurrence.
Abstract:
Last year, in 2001, the results of several major clinical trials have been published, concerning hypertensive patients with type 2 diabetes (IRMA, RENAAL and IDNT studies) and patients with previous strokes. Angiotensin II antagonists (irbesartan and losartan) are able to reduce the rate of progression of diabetic nephropathy in hypertensive patients with type 2 diabetes. This preventive effect occurs independently of the stage of renal dysfunction (early stage in IRMA, patent nephropathy in RENAAL and advanced nephropathy in IDNT). The PROGRESS study shows that the decrease in blood pressure, in response to an ACE inhibitor/diuretic bitherapy (perindopril/indapamide), in patients with previous minor stroke or transient ischaemic attack, reduces significantly the risk of recurrent stroke.